A new device developed in the DeSimone lab and studied in collaboration with other researchers at UNC gives new hope for improving the treatment of pancreatic cancer and other highly difficult-to-treat cancers. Dr. James Byrne led the research effort. Findings were published on Feb. 4 in Science Translational Medicine and have been widely featured. Results show unprecedented tumor shrinkage in murine models of human cancer using the device compared to standard IV treatments. Improving the ability to shrink pancreatic tumors could open the door for more patients to qualify for life-saving surgeries. The device is the first known use of iontophoresis to treat pancreatic tumors. Using an electrical current, the device drives chemotherapeutic drugs directly into a tumor, creating higher drug concentrations in the tumor without increasing systemic toxicity. In 2014, Byrne achieved his PhD as a member of the DeSimone group; he is now completing his final stretch of medical school at UNC to obtain his MD.